US HB573 | 2009-2010 | 111th Congress
Status
Sponsorship: Bipartisan Bill
Status: Introduced on January 15 2009 - 25% progression, died in committee
Action: 2009-01-16 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on January 15 2009 - 25% progression, died in committee
Action: 2009-01-16 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from commencing to manufacture, market, sell, or distribute a generic version of such drug from the time of the receipt of notice from the generic manufacturer that an abbreviated new drug application has been submitted for approval until the expiration or forfeiture of the exclusivity period granted to the generic manufacturer.
Title
To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.
Sponsors
| Rep. Marion Berry [D-AR] | Rep. Jo Emerson [R-MO] | Rep. Dennis Moore [D-KS] | Rep. Zach Wamp [R-TN] |
History
| Date | Chamber | Action |
|---|---|---|
| 2009-01-16 | Referred to the Subcommittee on Health. | |
| 2009-01-15 | Referred to the House Committee on Energy and Commerce. |
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/111th-congress/house-bill/573/all-info |
| Text | https://www.congress.gov/111/bills/hr573/BILLS-111hr573ih.pdf |
